Biocon And Juno Partner On Liraglutide In Canada
Cites Potential Addressable Canadian Market Of Around $100m For Diabetes Treatment
Biocon has announced a partnership with Juno Pharmaceuticals to market its liraglutide diabetes treatment in Canada, where the firms see a market worth as much as $100m.
